What is X saying about Claude 4.7? I had Levangie Labs @blevlabs look through tens of thousands of X posts here done today. And give me all points of view about your reactions, and compare it to the other popular models. On the audio space (AI Jam) I'm on one guy said he hated
GENERATIVE AI
-
OpenAI Releases GPT-Rosalind for Life Sciences Research
By
–
OpenAI released GPT-Rosalind today, a frontier reasoning model purpose-built for life sciences research, available in trusted-access preview to customers like Amgen, Moderna, and the Allen Institute.
— Chubby♨️ (@kimmonismus) 16 avril 2026
On the benchmarks, it's competent rather than revolutionary, leading on… https://t.co/BL9RnVlJ2ZOpenAI released GPT-Rosalind today, a frontier reasoning model purpose-built for life sciences research, available in trusted-access preview to customers like Amgen, Moderna, and the Allen Institute. On the benchmarks, it's competent rather than revolutionary, leading on
-
Human Scientists Outperform Best AI Agents on Complex Tasks
By
–
Human scientists trounce the best #AIAgents on complex tasks
by Nicola Jones @Nature Learn more: https://
bit.ly/4vNPzmv #GenerativeAI #ArtificialIntelligence #MachineLearning #ML -
GPT-Rosalind: Advanced Life Sciences AI Model Series
By
–
GPT-Rosalind, our Life Sciences model series, is optimized for scientific workflows, with stronger performance in protein and chemical reasoning, genomics analysis, biochemistry knowledge, and scientific tool use.
-
OpenAI Launches Life Sciences AI Model Series for Qualified Customers
By
–
Our Life Sciences model series is available as a research preview starting today for qualified customers including @Amgen
, @moderna_tx
, the @AllenInstitute
, and @thermofisher Scientific through ChatGPT, Codex, and the API. -
GPT-Rosalind: Frontier AI Model for Biology and Drug Discovery
By
–
Introducing GPT-Rosalind, our frontier reasoning model built to support research across biology, drug discovery, and translational medicine. pic.twitter.com/PubLU0FkSv
— OpenAI (@OpenAI) 16 avril 2026Introducing GPT-Rosalind, our frontier reasoning model built to support research across biology, drug discovery, and translational medicine.
-
AI Accelerates Drug Discovery and Development Timelines
By
–
On average, it takes roughly 10 to 15 years to go from target discovery to regulatory approval for a new drug in the United States.
— OpenAI (@OpenAI) 16 avril 2026
Advanced AI systems can help researchers move faster — not just by making existing work more efficient, but by helping scientists explore more… pic.twitter.com/IbNGXNguD0On average, it takes roughly 10 to 15 years to go from target discovery to regulatory approval for a new drug in the United States. Advanced AI systems can help researchers move faster — not just by making existing work more efficient, but by helping scientists explore more
-
Claude Opus 4.7 Excels in Autonomous AI Agent Tasks
By
–
Claude Opus 4.7 immediately impresses. AI Foundations Engineering Manager @Ryfeus
's take: "In putting it to work on everything from automated evaluations to agent simulations and other complex tasks involving longer autonomy horizons or more demanding environments, it's -
Free Year of FactoryAI with Lenny’s Newsletter Subscription
By
–
Get a free year of @FactoryAI with your Lenny's Newsletter subscription
-
Codex Gets Major Updates With New Computer Use Feature
By
–
Lots of major improvements to Codex! Computer use is a real update for me; it feels even more useful than I expected. It can use all of the apps on your Mac, in parallel and without interfering with your direct work.